Physician profile
Stephen Nester
NPI 1871574582
$11,944.94
in general payments reported to CMS, 2019-2025
54 companies · $31.60 in 2025
The $31.60 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,091 · 2020: $1,313 · 2021: $2,561 · 2022: $2,177 · 2023: $2,010 · 2024: $1,762 · 2025: $31.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,788 · Entertainment: $14.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,787.97 |
| Entertainment | $14.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,397.00 | 2021-2025 | |
| Pfizer INC. | $1,253.89 | 2019-2024 | |
| Glaxosmithkline, LLC. | $1,118.85 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $1,098.47 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $801.63 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $600.22 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $534.17 | 2019-2024 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $495.94 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Astellas Pharma US INC | $396.19 | 2019-2023 | Myrbetriq, Veozah |
| E.R. Squibb & Sons, L.L.C. | $328.09 | 2019-2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $322.28 | 2019-2024 | |
| Amgen INC. | $314.02 | 2019-2024 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.66 | 2019-2024 | Xifaxan |
| Allergan, INC. | $277.00 | 2019-2020 | |
| Daiichi Sankyo INC. | $209.14 | 2021-2023 | Injectafer |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Nester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.